Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been
studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable …

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent
cytokines in mediating antitumor activity in a variety of preclinical models. Through …

To engineer patient‐derived cells into therapy‐purposed biologics is a promising solution to
realize personalized treatments. Without using gene‐editing technology, a live cell‐typed …

Achievement of potent immunoresponses against self/tumor antigens and effective
therapeutic outcome against advanced tumors remain major challenges in cancer …

Cytokines are immunoregulatory proteins involved in many pathological states with
promising potential as therapeutic agents. A diverse array of cytokines has been studied in …

Cancer is a multi-faceted disease comprising complex interactions between neoplastic and
normal cells. Over the past decade, there has been considerable progress in defining the …

Purpose. With improvements in breast imaging and image-guided interventions, there is
interest in ablative techniques for breast cancer. Cryosurgery initiates inflammation and …

Research in novel drug delivery systems is being explored competitively in order to attain
maximum therapeutic effect while minimizing the adverse effects. Despite several …

Background: Advanced stage cancers with a suppressive tumor microenvironment (TME)
are often refractory to immune checkpoint inhibitor (ICI) therapy. Recent studies have shown …

For a valid cytokine immunotherapy of malignancies, a suitable delivery system that ensures
slow-release of cytokines is required, because short half-life in vivo of the molecules ruins …